Evidence map›Paper›PMID 42572428›Full record

ArticleEuropean journal of neurology2026

Reply to: "A Network Meta-Analysis of Hereditary Transthyretin Amyloidosis With Polyneuropathy Supports a Class Effect, Not a Ranking of Individual Drugs".

Gonçalo Nuno da Silva Duarte, Tiago Luís Gonçalves Neves Machado, Filipe André Brogueira Rodrigues, Isabel Conceição, Davide Pareyson, João Nuno Marques Parracho Guerra da Costa, task force of the EAN/PNS joint guideline for the management of neurological manifestations in hereditary transthyretin amyloidosis

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gonçalo Nuno da Silva DuarteUnidade de Farmacologia Clínica, Unidade Local de Saúde de Santa Maria, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-7802-1897
Tiago Luís Gonçalves Neves MachadoLaboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8930-4382
Filipe André Brogueira RodriguesLaboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-5567-7938
Isabel ConceiçãoDepartamento de Neurociências e Saúde Mental, ULS de Santa Maria, CAML, and Instituto de Fisiologia, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0003-0934-9631
Davide PareysonUnit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID https://orcid.org/0000-0001-6854-765X
João Nuno Marques Parracho Guerra da CostaLaboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-5831-4921
task force of the EAN/PNS joint guideline for the management of neurological manifestations in hereditary transthyretin amyloidosis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

gene silencershereditary transthyretin amyloidosisnetwork meta‐analysispolyneuropathytreatment ranking

Identifiers

PMID42572428
PMCPMC13454732

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.